SRR608230
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.442
- PANCREAS_BETA_CELLS+0.412
- ALLOGRAFT_REJECTION+0.392
- ANGIOGENESIS+0.387
- KRAS_SIGNALING_DN+0.357
- INTERFERON_GAMMA_RESPONSE+0.341
- COAGULATION+0.334
- IL6_JAK_STAT3_SIGNALING+0.322
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.320
- INFLAMMATORY_RESPONSE+0.312
Top 10 suppressed
- MYC_TARGETS_V2-0.487
- DNA_REPAIR-0.470
- OXIDATIVE_PHOSPHORYLATION-0.423
- MYC_TARGETS_V1-0.418
- UNFOLDED_PROTEIN_RESPONSE-0.415
- G2M_CHECKPOINT-0.392
- E2F_TARGETS-0.385
- MITOTIC_SPINDLE-0.353
- PI3K_AKT_MTOR_SIGNALING-0.279
- NOTCH_SIGNALING-0.265
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR820379 | GTEX | — | 0.934 |
| 2 | SRR1397906 | GTEX | — | 0.924 |
| 3 | SRR1319539 | GTEX | — | 0.924 |
| 4 | SRR601006 | GTEX | — | 0.920 |
| 5 | SRR1489971 | GTEX | — | 0.913 |
| 6 | SRR1468141 | GTEX | — | 0.912 |
| 7 | ERR2208964 | — | — | 0.911 |
| 8 | SRR8943034 | — | — | 0.911 |
| 9 | MDT-AP-1215 | Med | Medulloblastoma | 0.910 |
| 10 | SRR1468574 | GTEX | — | 0.910 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.442 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.412 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.392 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.387 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.357 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.341 | Idelalisib | — uncovered |
| COAGULATION | 0.334 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.322 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.312 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.298 | Idelalisib | — uncovered |
| MYOGENESIS | 0.268 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.232 | Idelalisib | — uncovered |
| COMPLEMENT | 0.231 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.226 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.205 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.199 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.171 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.139 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.115 | Remibrutinib | — uncovered |